# A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

> **NCT03714022** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 140 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT03714022
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2019-04-02
- **Final completion:** 2019-04-02
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03714022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03714022, "A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03714022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*